IF 3 3区医学

Pathology Pub Date : 2025-08-29 DOI: 10.1016/j.pathol.2025.06.009

Julian Leto, Judith Spies, Linda Tran, Irene Luo, Alex Stoyanov, Peter Bradhurst, Nicolás Urriola

{"title":"Validation and optimisation of a commercial cell-based assay for detection of nodo-paranodal antibodies.","authors":"Julian Leto, Judith Spies, Linda Tran, Irene Luo, Alex Stoyanov, Peter Bradhurst, Nicolás Urriola","doi":"10.1016/j.pathol.2025.06.009","DOIUrl":"https://doi.org/10.1016/j.pathol.2025.06.009","url":null,"abstract":"A minority of patients fulfilling diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been found to have autoantibodies against components of nodal and paranodal structures in peripheral nerves. These autoantibodies may confer distinct clinical features, including a lower likelihood of response to treatment with intravenous immunoglobulin (IVIg). There are currently limited options available for the detection of these autoantibodies in the diagnostic setting. We tested serum samples from 30 patients with CIDP, 40 disease controls [20 with myasthenia gravis and 20 with systemic lupus erythematosus (SLE)] and 52 healthy controls for the presence of antibodies against neurofascin 155 (NF155), neurofascin 186 (NF186), contactin-1 (CNTN1) and the contactin-1/contactin-associated protein 1 (CNTN1/CASPR1) complex using a commercial transfected HEK293 cell-based indirect immunofluorescence immunoassay (EUROImmun). We detected nodo-paranodal antibodies in six of 30 CIDP patients, including five who had previously tested positive for nodo-paranodal antibodies using enzyme-linked immunosorbent assay (ELISA). There was one positive test for anti-CNTN1 in a disease control with SLE and membranous glomerulonephritis, with no positive tests in healthy controls. We modified the manufacturer's staining protocol by using biotinylated anti-IgG and streptavidin-FITC labelling, which increased the analytical sensitivity of the assay. Our modified assay retained its robustness in the presence of interfering substances (haemolysed, lipaemic and icteric samples) and serum with high non-specific background immunofluorescent staining. We successfully modified and validated a commercial indirect immunofluorescence immunoassay for the qualitative detection of antibodies against NF155, NF186, CNTN1 and CNTN1/CASPR1. This could lead to more rapid diagnosis of patients with these autoantibodies, avoiding costly and ineffective treatments.","PeriodicalId":19915,"journal":{"name":"Pathology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology of respiratory syncytial virus within a New South Wales-based multi-centre health district between 2018 and 2024 in Australia. 2018年至2024年澳大利亚新南威尔士州多中心卫生区内呼吸道合胞病毒的流行病学研究

IF 3 3区医学

Pathology Pub Date : 2025-08-29 DOI: 10.1016/j.pathol.2025.06.011

Zubair Akhtar, Adriana Notaras, Essa Tawfiq, Mohana Kunasekaran, C Raina MacIntyre, William Rawlinson, Gregory J Walker

{"title":"Epidemiology of respiratory syncytial virus within a New South Wales-based multi-centre health district between 2018 and 2024 in Australia.","authors":"Zubair Akhtar, Adriana Notaras, Essa Tawfiq, Mohana Kunasekaran, C Raina MacIntyre, William Rawlinson, Gregory J Walker","doi":"10.1016/j.pathol.2025.06.011","DOIUrl":"https://doi.org/10.1016/j.pathol.2025.06.011","url":null,"abstract":"Respiratory syncytial virus (RSV) epidemiology in Australia is unclear given recent advances in diagnostic testing, COVID-19 interventions, and under-recognition in older adults. Data are needed to inform new RSV vaccine use. We analysed laboratory data from all viral respiratory reverse transcription quantitative polymerase chain reaction (RT-qPCR) diagnostic tests conducted at New South Wales (NSW) Health Pathology in the South Eastern Sydney and Illawarra Health Service from 2018 to 2024. Panel and descriptive analyses were used to report annual RSV testing and detection by age group, care setting, and co-infection with other respiratory viruses using Stata v.18. Of 370,126 unique episodes tested for RSV, there were 13,293 (3.6%) detections. Public health measures for COVID-19 significantly impacted RSV circulation in 2020, with detections nearly absent in the winter season (June-August) and an off-season epidemic occurring in the summer. Annual testing and detection peaked in 2022 and was considerably higher than in pre-pandemic years (testing 6.3-fold and detection 3.4-fold higher than in 2019, respectively). Across the study period, incidence was highest in children aged <5 years (1,613 per 100,000 population). Among older adults (≥60 years of age), prevalence was 125 per 100,000. Testing was primarily performed in outpatients (71%), of which emergency departments were the most frequent care setting (49%). Of all detections, 2,713 (20.4%) had co-infections, with the most commonly co-detected viruses being rhinovirus (37%) and bocavirus (17%). RSV testing increased from 2022 due to expanded respiratory screening, RSV becoming a notifiable disease, and COVID-19 epidemics. Multiplex RT-qPCR testing increased RSV detection, but testing bias exists, with children tested more than adults. Continued surveillance across age groups is essential to assess the impact of new immunisation strategies.","PeriodicalId":19915,"journal":{"name":"Pathology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of macro-aspartate aminotransferase after chemotherapy for locally advanced colorectal cancer. 局部晚期结直肠癌化疗后大天冬氨酸转氨酶1例。

IF 3 3区医学

Pathology Pub Date : 2025-08-13 DOI: 10.1016/j.pathol.2025.06.006

Georgia Zeng, Sandhya Ramakrishna, Maria Charan, David Sullivan, Sarah Sutherland, Ken Liu

引用次数: 0

Rat bite fever diagnosed with clinical metagenomics. 临床宏基因组学诊断鼠咬热。

IF 3 3区医学

Pathology Pub Date : 2025-08-13 DOI: 10.1016/j.pathol.2025.06.008

Sanmarié Schlebusch, Rikki M A Graham, Susan Moss, Amy V Jennison, Stephen Boyle, Nathan Milne

引用次数: 0

Distribution of common clinical chemistry measurands in a healthy population: a resource for indirect reference interval studies. 健康人群中常见临床化学指标的分布：间接参考区间研究的资源。

IF 3 3区医学

Pathology Pub Date : 2025-08-11 DOI: 10.1016/j.pathol.2025.06.007

Christopher-John L Farrell, Gus Koerbin, Julia M Potter, Peter E Hickman

引用次数: 0

Primary lung ameloblastic carcinoma: an unreported primary lung tumour. 原发性肺成釉细胞癌：一种未报道的原发性肺肿瘤。

IF 3 3区医学

Pathology Pub Date : 2025-08-06 DOI: 10.1016/j.pathol.2025.05.017

Mingfang Sun, Hongjiu Ren, Lin Fu, Jian Wang, Ping Yu, Hongtao Xu, Xuyong Lin

引用次数: 0

A challenging case of an epithelioid haemangioma of bone with novel FOS::ANKRD28 gene fusion. 具有新的FOS::ANKRD28基因融合的骨上皮样血管瘤的一个具有挑战性的病例。

IF 3 3区医学

Pathology Pub Date : 2025-08-05 DOI: 10.1016/j.pathol.2025.06.005

Fleur Cordier, Liesbeth Ferdinande, Siebe Loontiens, Joni Van der Meulen, Jo Van Dorpe, David Creytens

引用次数: 0

A case of primary intestinal T-follicular helper cell lymphoma. 原发性肠道t滤泡辅助细胞淋巴瘤1例。

IF 3 3区医学

Pathology Pub Date : 2025-07-29 DOI: 10.1016/j.pathol.2025.05.012

Reiji Muto, Hiroaki Miyoshi, Seiya Kato, Takahiro Mizutani, Noriyuki Saito, Koichi Ohshima

引用次数: 0

Micronodular perivascular epithelioid cell tumour of the appendix. 阑尾小结节性血管周围上皮样细胞瘤。

IF 3 3区医学

Pathology Pub Date : 2025-07-29 DOI: 10.1016/j.pathol.2025.05.016

Yueh Lee, Meng-Fang Li, Po-Yen Kuo, Yueh-Hung Chou

引用次数: 0

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is extensively expressed in the microenvironment of nodular lymphocyte-predominant Hodgkin lymphoma and T-cell-/histiocyte-rich large B-cell lymphoma. 具有Ig和ITIM结构域的t细胞免疫受体（TIGIT）在结节性淋巴细胞为主的霍奇金淋巴瘤和富含t细胞/组织细胞的大b细胞淋巴瘤的微环境中广泛表达。

IF 3 3区医学

Pathology Pub Date : 2025-07-29 DOI: 10.1016/j.pathol.2025.05.013

Georgia Karpathiou, Somaia Chokoud, Mousa Mobarki, Michel Péoc'h

{"title":"T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is extensively expressed in the microenvironment of nodular lymphocyte-predominant Hodgkin lymphoma and T-cell-/histiocyte-rich large B-cell lymphoma.","authors":"Georgia Karpathiou, Somaia Chokoud, Mousa Mobarki, Michel Péoc'h","doi":"10.1016/j.pathol.2025.05.013","DOIUrl":"https://doi.org/10.1016/j.pathol.2025.05.013","url":null,"abstract":"T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) is a molecule involved in the immune escape of tumour cells and is a target of immunotherapy. Recently, TIGIT has gained attention as a crucial player in the tumour microenvironment (TME) of lymphomas. TIGIT immunohistochemical expression has not been thoroughly studied in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and T-cell-/histiocyte-rich large B-cell lymphoma (THRLBCL). We studied TIGIT's immunohistochemical expression in 27 whole-lymph-node sections from 19 patients diagnosed with NLPHL and eight patients diagnosed with THRLBCL. TIGIT was consistently expressed in the TME of all lymphomas, exhibiting strong membranous staining. The TME expression ranged from 40% to 90% (median 70%). Rosettes around tumour cells were common in 23 (85.1%) cases. TIGIT was expressed by tumour cells in four cases (14.8%). NLPHL and THRLBCL harbour extensive TIGIT expression in their microenvironment, often in the form of peritumoural rosettes; some express TIGIT in tumor cells. Despite a small cohort, our results suggest that patients may benefit from TIGIT inhibition.","PeriodicalId":19915,"journal":{"name":"Pathology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144964722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathology最新文献